Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer

Table 5

Clinical efficacy of Trastuzumab and Lapatinib as monotherapy agents for metastatic breast cancer [26, 27, 30, 39].

Study	No. of patients	Initial and following dose	OR (%)	Median TOP and range (months)
Trastuzumab
Baselga et al. [27]	105	8 mg/kg, 6 mg/kg triweekly	19	3.4 (range 0.6–23.6)
Cobleigh et al. [26]	222	4 mg/kg, 2 mg/kg weekly	15	3.1 (range 0–≥28)
Vogel et al. [39]	114	4 mg/kg, 2 mg/kg weekly	26	3.8 (range 3.3–5.3)
		Or 8 mg/kg, 4 mg/kg weekly
Lapatinib
Gomez et al. [30]	69	1500 mg once daily	24	4.4 (range 0.5–23)
		Or 500 mg twice daily

OR: Overall response rate; TOP: Time to progression.
To date, most lapatinib therapies are still in progress and currently being evaluated.